According to Zacks, “ImmunityBio Inc. is a late-clinical-stage immunotherapy company developing therapies which drive immunogenic mechanisms for defeating cancers and infectious diseases. The company’s immunotherapy platform activates both the innate and adaptive immune systems. ImmunityBio Inc., formerly known as NantKwest Inc., is based in CULVER CITY, Calif. “
IBRX traded up $0.08 during trading on Tuesday, reaching $5.01. The stock had a trading volume of 1,405,651 shares, compared to its average volume of 1,542,971. ImmunityBio has a 1-year low of $4.81 and a 1-year high of $19.72. The stock has a 50 day moving average of $6.09 and a two-hundred day moving average of $6.84.
ImmunityBio Company Profile (Get Rating)
ImmunityBio, Inc, a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems.
- Get a free copy of the StockNews.com research report on ImmunityBio (IBRX)
- Insiders Are Selling Palo Alto Networks
- Greenbrier Companies Stock has Green in its Future
- 3 Bank Stocks That Are Ready to Handle Whatever the Fed Throws at Them
- Tilray Stock Has Better Days Ahead
- Headwinds Mount For Carmax, Don’t Count On Higher Share Prices
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.